title: Effect of antagonists vs agonists on in vitro fertilization outcome.
abstract: OBJECTIVE
  To compare outcome following in vitro fertilization-embryo transfer (IVF-ET) using controlled ovarian hyperstimulation (COH) regimens using either the gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate vs the GnRH antagonist ganirelix.
  
  
  METHODS
  Women needing IVF for conception were randomly assigned to 300 IU of gonadotropins with ganirelix used in the follicular phase when a follicle with a 14 mm average diameter was attained vs a regimen using leuprolide acetate from the mid-luteal phase of the previous cycle.
  
  
  RESULTS
  There were no differences found in clinical, ongoing, delivered pregnancy rates or implantation rates between groups.
  
  
  CONCLUSIONS
  The use of GnRH antagonists do not seem to reduce IVF outcome compared to using GnRH agonists in COH regimens.
authors.affiliation: The University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School at Camden, Cooper Hospital/University Medical Center, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, NJ, USA.
authors.forename: M L
authors.initials: ML
authors.lastname: Check
authors.forename: J H
authors.initials: JH
authors.lastname: Check
authors.forename: J K
authors.initials: JK
authors.lastname: Choel
authors.forename: E
authors.initials: E
authors.lastname: Davies
authors.forename: D
authors.initials: D
authors.lastname: Kiefer
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D004624:Embryo Transfer / Q000706:statistics & numerical data; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D005307:Fertilization in Vitro / Q000379:methods*; D037201:Follicle Stimulating Hormone, beta Subunit / Q000627:therapeutic use; D005498:Follicular Phase; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D006727:Hormone Antagonists / Q000627:therapeutic use*; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use*; D008183:Luteal Phase; D008596:Menotropins / Q000627:therapeutic use; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies
chemical_list: D005300:Fertility Agents, Female; D037201:Follicle Stimulating Hormone, beta Subunit; D006727:Hormone Antagonists; D007987:Gonadotropin-Releasing Hormone; D008596:Menotropins; D016729:Leuprolide; C061018:ganirelix